Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Incidence and course of EBV viremia after allogeneic HSCT for CAEBV.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.


  1. Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, et al. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022;97:780–90.

    Article  CAS  PubMed  Google Scholar 

  2. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012;119:673–86.

    Article  CAS  PubMed  Google Scholar 

  3. Onishi Y, Onodera K, Fukuhara N, Kato H, Ichikawa S, Fujiwara T, et al. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders. Int J Hematol. 2022;115:873–81.

    Article  CAS  PubMed  Google Scholar 

  4. Arai A, Sakashita C, Hirose C, Imadome KI, Yamamoto M, Jinta M, et al. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers. Bone Marrow Transpl. 2016;51:879–82.

    Article  CAS  Google Scholar 

  5. Kawada JI, Kamiya Y, Sawada A, Iwatsuki K, Izutsu K, Torii Y, et al. Viral DNA loads in various blood components of patients with Epstein-Barr virus-positive T-cell/natural killer cell lymphoproliferative diseases. J Infect Dis. 2019;220:1307–11.

    Article  CAS  PubMed  Google Scholar 

  6. Bontems S, Boreux R, Capraro V, Huynen P, Descy J, Melin P, et al. Evaluation of the Abbott RealTime quantitative CMV and EBV assays using the maxCycle protocol in a laboratory automation context. J Virol Methods. 2019;270:137–45.

    Article  CAS  PubMed  Google Scholar 

  7. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wei N, Wang Y, Wang J, Wu L, Wang Z. Characteristics of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein-Barr virus disease: favorable responses to rituximab. Bone Marrow Transpl. 2021;56:1449–51.

    Article  CAS  Google Scholar 

  9. Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4:404–13.

    Article  CAS  PubMed  Google Scholar 

  10. Venturini C, Houldcroft CJ, Lazareva A, Wegner F, Morfopoulou S, Amrolia PJ, et al. Epstein-Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV. Br J Haematol. 2021;195:249–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kinzel M, Kalra A, Khanolkar RA, Williamson TS, Li N, Khan F, et al. Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder. Transpl Cell Ther. 2023;29:43.e1–43.e8.

    Article  CAS  Google Scholar 

Download references


We would like to thank Rhalp Jaylord Valenzuela for his statistical expertise.

Author information

Authors and Affiliations



PPMV and MO designed the research, analyzed the data, and wrote the manuscript. All the authors contributed to data collection and review of the manuscript. All authors approved the final manuscript for publishing.

Corresponding author

Correspondence to Masahiro Onozawa.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vaswani, P.P.M., Onozawa, M., Hasegawa, Y. et al. Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease. Bone Marrow Transplant 58, 1397–1399 (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links